|Dr. Thomas Meier Ph.D.||Founder & Chairman||83.75k||N/A||1962|
|Mr. Dario Eklund||Chief Executive Officer||814.82k||N/A||1968|
|Mr. Andrew P. Smith CGMA, FCMA||Chief Financial Officer||N/A||N/A||1963|
|Mr. Oliver Strub||Executive VP, General Counsel & Secretary||N/A||N/A||1963|
|Mr. Günther Metz Ph.D.||Head of Business Development & Executive VP||N/A||N/A||1958|
|Mr. Shabir Hasham M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Stephanie Brown B.Sc., M.B.A.||President of North America||N/A||N/A||1961|
|Mr. Marc Schrader||Head of Technical Development & Operations||N/A||N/A||N/A|
|Ms. Eva Kalias||Head of Investor Relations & Communications||N/A||N/A||N/A|
|Mr. Neville Kodkani M.D.||Head of Global Marketing & Partner Management||N/A||N/A||N/A|
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
Santhera Pharmaceuticals Holding AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.